Navigation Links
Temple, Fox Chase and Geisinger create Keystone Institute for Translational Medicine
Date:8/12/2008

Temple University School of Medicine, Fox Chase Cancer Center and Geisinger Health System today announced a research collaboration that will speed the translation of medical and health-related discoveries into significant advances in patient care.

As part of the agreement, the three institutions will form The Keystone Institute for Translational Medicine, based at Temple, to design and implement research on the genetic, behavioral, and social causes of such diseases as diabetes, hypertension, lung disease, obesity and specific cancers that disproportionately affect urban and rural Pennsylvanians.

"Together, we serve one of the most diverse patient populations in the country, putting us in a unique position to contribute significantly to translational research discoveries," said John M. Daly, M.D., dean of Temple University School of Medicine.

"We are excited to participate in The Keystone Institute for Translational Medicine," said J. Robert Beck, M.D., Fox Chase Cancer Center's senior vice president and chief academic officer. "Fox Chase Cancer Center has strong traditions in basic biomedical research, population science, and clinical trials in oncology. The Institute offers an opportunity to bridge these areas with outstanding partners to complete the cycle of bench-to-bedside-to-bench in many areas of medicine and among the diverse populations we all serve."

A special feature of the Institute is its virtual nature, which will enhance the collaboration through a social network, much like Facebook, thereby erasing the physical boundaries that separate Temple and Fox Chase researchers in Philadelphia and those at Geisinger Health System in Danville.

An overarching goal will be to engage patients in research as part of the healthcare delivery process. One such project already underway in urban Philadelphia and rural Danville is investigating the effectiveness of church-based weight loss support groups in helping people lose weight and maintain weight loss.

The three institutions are jointly pursuing a place within the National Institutes of Health's Clinical and Translational Science Award (CTSA) consortium, a network of medical research institutions across the nation.

In 2006, Temple was awarded the National Institutes of Health Clinical and Translational Science Planning Grant, which helps prepare institutions to become full-fledged CTSAs. Support from this grant has led to the master's program in Clinical Research and Translational Sciences, as well as the training and education of faculty in translational science research.

"This collaboration allows us to move beyond standard clinical and research practices to play a large role in moving knowledge from the bench to the bedside," said Glenn D. Steele, M.D., Ph.D., president and CEO of Geisinger Health System. "The synergy is expected to lead to major new therapies that can be safely and efficiently delivered to a broader healthcare market."


'/>"/>

Contact: Eryn Jelesiewicz
dobeck@temple.edu
215-707-0730
Temple University
Source:Eurekalert

Related medicine news :

1. Care Investment Trust Inc. Announces an Agreement in Principle for CIT Healthcare to Purchase Mortgage Assets and Reduce Management Fee
2. China Medical Technologies Announces Concurrent Offerings of $150 Million of Convertible Senior Notes and Purchased ADSs Pursuant to ADS Issuance and Repurchase Agreements
3. Leading Neurosurgical Center in Moscow Purchases CyberKnife System to Expand Ability to Treat Brain and Spinal Tumors
4. HealthSouth Finalizes Purchase of New Jersey Rehabilitation Hospital
5. Hillenbrand, Inc. Board of Directors Approves $100M Share Repurchase Program
6. Wyeth Consumer Healthcare Signs Agreement to Purchase ThermaCare from Procter & Gamble
7. AmeriCares Purchases 2nd BLU-MED Deployable Field Hospital for China Earthquake Relief
8. NBTY Closes on Purchase of Leiner Health Products
9. Edwards Lifesciences Board Approves New $250 Million Share Repurchase Program
10. Somanetics Announces Share Repurchase Program Increased By $15 Million
11. Assurance Investment Partners Purchases Arison Insurance Services from Anthem Blue Cross and Blue Shield
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... Appleton, WI (PRWEB) , ... March 28, 2017 ... ... how self-funded health plans work, the Self-Funding Success website has recently developed and ... about Self-Funded Health Plans ” was created based on common inquiries the site’s ...
(Date:3/28/2017)... ... March 28, 2017 , ... Prominant bariatric surgeon ... is thrilled to offer the recently FDA-approved Obalon Balloon System to his patients. ... SkyLex Advanced Surgical’s already comprehensive list of weight-loss services. Dr. Liu is ...
(Date:3/28/2017)... ... March 28, 2017 , ... Oily skin is a common and unwelcomed occurrence in ... has a lot to offer to the discussion of dealing with excess skin oil. ... there are many home remedies that can help remove the oily shine while keeping the ...
(Date:3/27/2017)... ... March 27, 2017 , ... New patients who have sleep apnea ... treatment, with or without a referral. Sleep apnea is often left untreated because patients ... morning headaches and chronic snoring. , Dr. Braasch seeks to raise awareness of ...
(Date:3/27/2017)... London UK (PRWEB) , ... March 27, 2017 ... ... agility and ability to gain site attention and engagement over the household brands ... educational webinar will discuss how partnering with the right outsourcing payments ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... 28, 2017 The global market ... with the top three companies, namely Shimadzu Corporation, Thermo ... significant 49% of the overall market in 2015, observes ... landscape is intensely competitive and has few players, most ... These factors have restricted the entry of new players ...
(Date:3/28/2017)... TEL AVIV, Israel , March 28, 2017 ... . This new business entity, Emosis Ltd, headquartered in ... and development of novel assays complementing the mother company existing technology ... support commercialization and sales development of Emosis kits. ... This strategic move starts building Emosis ...
(Date:3/28/2017)... 28, 2017  CASI Pharmaceuticals, Inc. (Nasdaq: CASI), ... cancer and other unmet medical needs, announced today ... Cancer Research annual meeting.  The first poster to ... "Evaluation of ENMD-2076 in Combination with Anti-PD1 in ... to be presented on April 4 is entitled ...
Breaking Medicine Technology: